These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9949361)

  • 1. Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment.
    Lee RE; Tartell PB; Karmody CS; Hunter DD
    Otolaryngol Head Neck Surg; 1999 Feb; 120(2):255-61. PubMed ID: 9949361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyclonal neural cell adhesion molecule antibody prolongs the effective duration time of botulinum toxin in decreasing muscle strength.
    Guo Y; Pan L; Liu W; Pan Y; Nie Z; Jin L
    Neurol Sci; 2015 Nov; 36(11):2019-25. PubMed ID: 26150164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct patterns of motor nerve terminal sprouting induced by ciliary neurotrophic factor vs. botulinum toxin.
    Wright MC; Cho WJ; Son YJ
    J Comp Neurol; 2007 Sep; 504(1):1-16. PubMed ID: 17614103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Electrophysiological study for comparing the effect of biological activity between type A botulinum toxins in rat gastrocnemius muscle.
    Kim CS; Jang WS; Son IP; Nam SH; Kim YI; Park KY; Kim BJ; Kim MN
    Hum Exp Toxicol; 2013 Sep; 32(9):914-20. PubMed ID: 23475433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section.
    Sulica L; Blitzer A; Brin MF; Stewart CF
    Ann Otol Rhinol Laryngol; 2003 Jun; 112(6):499-505. PubMed ID: 12834116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The central action of botulinum toxin type A assessed by brain auditory and somatosensory evoked potentials].
    Sławek J; Recławowicz D
    Neurol Neurochir Pol; 2004; 38(2):93-9. PubMed ID: 15307601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
    Dessy LA; Fallico N; Mazzocchi M; Scuderi N
    Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Indications and management of botulinum toxin].
    Singer C
    Rev Neurol; 1999 Jul 16-31; 29(2):157-62. PubMed ID: 10528331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Botulinum A toxin in the treatment of focal dystonias].
    Domzał TM
    Neurol Neurochir Pol; 1998; 32 Suppl 1():35-44. PubMed ID: 9608551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence-based medicine in botulinum toxin therapy for cervical dystonia.
    Ceballos-Baumann AO
    J Neurol; 2001 Apr; 248 Suppl 1():14-20. PubMed ID: 11357233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulating neuromuscular junction density changes in botulinum toxin-treated orbicularis oculi muscle.
    Harrison AR; Berbos Z; Zaldivar RA; Anderson BC; Semmer M; Lee MS; McLoon LK
    Invest Ophthalmol Vis Sci; 2011 Feb; 52(2):982-6. PubMed ID: 21087967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of synaptotagmin II to the axolemma of botulinum type-A poisoned mouse motor endings during enhanced quantal acetylcholine release.
    Angaut-Petit D; Molgó J; Faille L; Juzans P; Takahashi M
    Brain Res; 1998 Jun; 797(2):357-60. PubMed ID: 9666170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of botulinum toxins in oral and maxillofacial surgery.
    Majid OW
    Int J Oral Maxillofac Surg; 2010 Mar; 39(3):197-207. PubMed ID: 19959337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nerve terminal sprouting in botulinum type-A treated mouse levator auris longus muscle.
    Juzans P; Comella JX; Molgo J; Faille L; Angaut-Petit D
    Neuromuscul Disord; 1996 May; 6(3):177-85. PubMed ID: 8784806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of Yiqi Huayu Recipe on neural cell adhesion molecule in rats with lumbar nerve root compression].
    Zhou CJ; Ma YH; Shu B; Wang YJ; Shi Q
    Zhong Xi Yi Jie He Xue Bao; 2006 Mar; 4(2):175-80. PubMed ID: 16529695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Applications of botulinum toxin in Neurology].
    Garcia-Ruiz PJ
    Med Clin (Barc); 2013 Jul; 141(1):33-6. PubMed ID: 23434466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of botulinum toxin in neurological indications.
    Ward AB; Molenaers G; Colosimo C; Berardelli A
    Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative neuromuscular histopathology of cricopharyngeal achalasia patients with and without previous botulinum toxin treatment.
    Merati AL; Tseng J; Blumin JH; Toohill RJ; Jaradeh S
    Ann Otol Rhinol Laryngol; 2007 May; 116(5):375-80. PubMed ID: 17561767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.